| 1 | Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. (Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR) Clin Genitourin Cancer 2022 Apr;20(2):165-175 4 Citations |
| 1 | Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. (Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS) Cancer 2022 Mar 15;128(6):1194-1205 52 Citations |
| 1 | Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. (Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P) BJU Int 2021 Aug;128(2):196-205 23 Citations |
| 1 | A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. (Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P) Eur Urol Oncol 2021 Jun;4(3):464-472 47 Citations |
| 1 | Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. (Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC) JCI Insight 2019 May 30;5(13) 34 Citations |
| 1 | Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion. (Han L, Gallan A, Paner GP) Am J Surg Pathol 2019 Apr;43(4):475-479 5 Citations |
| 1 | Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. (Rodriguez JF, Packiam VT, Boysen WR, Johnson SC, Smith ZL, Smith ND, Shalhav AL, Steinberg GD) J Endourol 2017 Jul;31(7):661-665 52 Citations |
| 1 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF) Clin Genitourin Cancer 2016 Dec;14(6):511-517 4 Citations |
| 1 | The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA) J Urol 2016 Jun;195(6):1903-10 12 Citations |
| 1 | A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. (Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, Briganti A, Montorsi F, Cathelineau X) World J Urol 2016 Feb;34(2):207-13 16 Citations |
| 1 | Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. (Ikeda S, Hansel DE, Kurzrock R) Cancer Treat Rev 2015 Sep;41(8):699-706 13 Citations |
| 2 | H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology. (Shah G, Zielonka J, Chen F, Zhang G, Cao Y, Kalyanaraman B, See W) J Urol 2014 Oct;192(4):1238-48 22 Citations |
| 1 | Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. (Kanojia D, Garg M, Saini S, Agarwal S, Parashar D, Jagadish N, Seth A, Bhatnagar A, Gupta A, Kumar R, Lohiya NK, Suri A) PLoS One 2013;8(12):e81348 35 Citations |
| 1 | Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 01;120(5):692-701 94 Citations |
| 1 | iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA) Urol Oncol 2014 Jan;32(1):45.e1-9 21 Citations |
| 1 | Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See W) J Urol 2014 Mar;191(3):823-9 7 Citations |
| 1 | HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Johnson B, See WA) J Urol 2013 Apr;189(4):1541-6 7 Citations |
| 1 | A case for routine tonometry to avoid postoperative visual loss. (Usoltsev NA, Shankar H, Zainer CM) Br J Anaesth 2011 Oct;107(4):648-9 2 Citations |
| 1 | The effects of physiological estrogen concentration on the immune response of urothelial carcinoma cells to bacillus Calmette-Guérin. (Guise AI, Chen F, Zhang G, See W) J Urol 2011 Jan;185(1):298-304 4 Citations |
| 1 | MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. (Chen F, Zhang G, Cao Y, Hessner MJ, See WA) J Urol 2009 Dec;182(6):2932-7 23 Citations |
| 1 | Clinical outcome following prostatic capsule- and seminal-sparing cystectomy for bladder cancer in 25 men. (Thorstenson A, O'connor RC, Ahonen R, Jonsson MN, Wijkstrom H, Akre O, Hosseini A, Wiklund NP, Henningsohn L) Scand J Urol Nephrol 2009;43(2):127-32 11 Citations |
| 1 | Case report: percutaneous management of transitional-cell carcinoma of the upper urinary tract using the bipolar resectoscope. (Storm DW, Fulmer BR) J Endourol 2007 Sep;21(9):1011-3 9 Citations |
| 1 | Renal infarction secondary to infiltrative transitional cell carcinoma. (Castle EP, Blackford T, Langenstroer P) J Urol 2004 Aug;172(2):477 |
| 1 | Renal-ovarian axis: a case report and review. (Gavallos G, Tawfik O, Herrell D, Langenstroer P) Urology 2003 Oct;62(4):749 15 Citations |
| 1 | Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. (Chen F, Langenstroer P, Zhang G, Iwamoto Y, See W) J Urol 2003 Nov;170(5):2009-13 44 Citations |
| 1 | Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. (Kuznetsov DD, Alsikafi NF, O'Connor RC, Steinberg GD) Expert Opin Pharmacother 2001 Jun;2(6):1009-13 22 Citations |
| 1 | Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. (Langenstroer P, Zacharias A, Almagro U, Dewire D) Urology 1996 Mar;47(3):442-4 21 Citations |
| 1 | Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. (Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD) J Urol 1994 Dec;152(6 Pt 2):2272-5 38 Citations |
| 1 | DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. (Sandlow J, Cohen MB, Robinson RA, Dreicer R, Williams RD) Urology 1994 Jun;43(6):787-91 16 Citations |
| 1 | Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. (Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R) J Intern Med 1993 Oct;234(4):417-20 44 Citations |
